Podcasts by AML Hub
The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy for more information.
Further podcasts by Scientific Education Support
Podcast on the topic Bildung
All episodes
How are new fludarabine conditioning combinations impacting transplant outcomes? from 2022-04-22T11:42
During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thess...
Listen
Should pre-transplant MRD be used to guide treatment in AML? from 2021-06-23T14:00:09
During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide ...
Listen
Can HMA maintenance therapy improve eligibility for HSCT? from 2021-03-17T12:12:46
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT?<...
Listen
ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML? from 2021-02-02T18:23:44
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Andrew Wei, The Alfred Hospital, Melbourne, AU, and Natasha S. Anstee, The Alfred Hospita...
Listen
Venetoclax combinations in mutant AML subtypes: IDH1/2 from 2021-01-25T13:41:32
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Daniel Pollyea, University of Colorado School of Medicine, Aurora, US, about venetoclax c...
Listen
Venetoclax combinations in mutant AML subtypes podcast: FLT3 from 2021-01-20T17:11:40
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about venetoclax combinations i...
Listen
Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML from 2021-01-20T17:08:39
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Courtney D. DiNardo, MD Anderson Cancer Center, Houston, US, about the use of venetoclax ...
Listen
How close are we to offering treatment tailored to mutational profile? from 2020-07-08T13:16:46
During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In...
Listen
Approaches and emerging therapies for TP53 AML from 2020-07-01T09:26:05
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to a member of our steering committee, Naval Daver, The University of Texas MD Anderson Cancer Center, Ho...
Listen
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease from 2020-06-24T16:29:19
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the AML Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisc...
Listen
Can CD47 antibody therapy be safely used for AML and MDS? from 2020-06-22T13:58:28
During the 25th Congress of the European Hematology Association (EHA), the AML Hub hosted a discussion between David Sallman, Moffitt Cancer Center, Tampa, US, and Steering Committee Member Nava...
Listen
How does the type of prior treatment affect the risk of therapy-related myeloid neoplasms? from 2020-06-09T14:19:59
During the American Society of Clinical Oncology (ASCO) Annual Meeting, Alexander Maurer from the AML Hub hosted a group discussion with Michael Ozga and Caner Saygin, both from The Ohio State U...
Listen